Research Articles
Pharmacokinetics of Probenecid Following Oral Doses to Human Volunteers

https://doi.org/10.1002/jps.2600711114Get rights and content

Abstract

The pharmacokinetics of probenecid were examined following single 0.5-, 1.0-, and 2.0-g oral doses to healthy male volunteers. Doses were administered following overnight fast, according to a randomized design. Plasma levels of probenecid were determined by high-pressure liquid chromatography (HPLC), using sulfamethazine as the internal standard. Mean peak probenecid levels of 35.3,69.6, and 148.6μg/ml were obtained at 3–4 hr following the 0.5-, 1.0-, and 2.0-g doses, respectively. Probenecid levels from the 0.5- and 1.0-g doses declined in apparent monoexponential fashion, with mean elimination half-lives of 4.2 and 4.9 hr. Interpretation of the 2.0-g data by a kinetic model incorporating first-order elimination resulted in a plasma drug half-life of 8.5 hr. When first-order elimination was replaced by a Michaelis-Menten-type function, the mean value of the resulting Vm/Km ratios was 0.20, equivalent to a plasma drug half-life [0.693/(Vm/Km)] of 3.8 hr. Plasma probenecid curves from all three dosages were successfully fitted to the saturable elimination model using nonlinear regression and numerical integration routines. The results suggest that probenecid elimination may be saturable at therapeutic dose levels.

REFERENCES (26)

  • S. Melethil et al.

    J. Pharm. Sci.

    (1976)
  • G. Levy

    J. Pharm. Sci.

    (1965)
  • M. Weinberger et al.

    J. Pediatr.

    (1977)
  • D.D.M. Tong et al.

    Math. Biosci.

    (1980)
  • R.F. Cunningham et al.

    Clin. Phar-macokinet.

    (1981)
  • W.P. Boger et al.

    J. Lab. Clin. Med.

    (1951)
  • P.G. Dayton et al.

    J. Pharmacol. Exp. Ther.

    (1963)
  • T.B. Tjandramaga et al.

    Pharmacology

    (1972)
  • A.M. Guarino et al.

    J. Pharmacol. Exp. Ther.

    (1968)
  • J.M. Perei et al.

    Life Sci.

    (1970)
  • P.G. Dayton et al.

    J. Pharmacol. Exp. Ther.

    (1967)
  • R.K. Harle et al.

    Analyst

    (1978)
  • Cited by (78)

    • Pharmacological urate-lowering approaches in chronic kidney disease

      2019, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Probenecid undergoes the extensive metabolism, including glucuronide conjugation and alkyl side chain oxidation, after which only 5–11% of unchanged Probenecid is excreted in urine. The metabolites are mainly eliminated through kidney [67–69]. The American College of Rheumatology guidelines recommend Probenecid as the first choice of uricosuric for urate-lowering treatment (ULT) but recommend against using Probenecid in cases where the GFR is less than 50 ml/min [39].

    • Emodin-induced hepatotoxicity was exacerbated by probenecid through inhibiting UGTs and MRP2

      2018, Toxicology and Applied Pharmacology
      Citation Excerpt :

      The aggravating hepatotoxicity of combination group was highly possible caused by the bidirectional interactions between emodin and probenecid. Pharmacokinetic experiment showed that the serum concentration of probenecid is highly dose-dependent in human (Selen et al., 1982; Wu et al., 2010), and thus aggravating hepatotoxicity might attribute to the increased accumulation of probenecid induced by emodin. Therefore, further studies will be needed to clarify the effect of emodin on the toxicokinetics of probenecid.

    • Transport of 3-fluoro-L-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [<sup>18</sup>F]FAMT positron emission tomography

      2016, Journal of Pharmacological Sciences
      Citation Excerpt :

      The accumulation of [125I]IMT in S2-like region let us speculate that OAT1 present in S2 segment (38) at least contributes to the renal accumulation of [125I]IMT, while, at the moment, the detailed tubular distribution is not determined for OAT10 and OCTN2. As shown in Fig. 5, [14C]FAMT transports by OAT1, OAT10 and OCTN2 are mostly inhibited by probenecid, furosemide and ethacrynic acid, suggesting that particularly probenecid with relatively higher plasma concentration at clinical dosage (40) could suppress the renal accumulation of [18F]FAMT in PET when administered at appropriate doses. It was furthermore reported for IMT that, in cultured human renal proximal tubule epithelial cells in vitro, the small portion of [125I]IMT uptake is inhibited by BCH, an inhibitor of amino acid transport systems L, B0 and B0,+ (34), in a Na+-dependent manner (28).

    • Urate-Lowering Therapy

      2016, Kelley and Firestein's Textbook of Rheumatology: Volumes 1-2, Tenth Edition
    View all citing articles on Scopus
    View full text